Elis Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-11-2024
- Paid Up Capital ₹ 0.70 M
as on 15-11-2024
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.61 M
as on 15-11-2024
- Revenue -18.88%
(FY 2023)
- Profit -315.74%
(FY 2023)
- Ebitda -14.73%
(FY 2023)
- Net Worth -17.13%
(FY 2023)
- Total Assets 5.54%
(FY 2023)
About Elis Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹2.61 M.
Sapna Kaushik and Ajay Juneja serve as directors at the Company.
- CIN/LLPIN
U85121DL2006PTC152273
- Company No.
152273
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Elis Pharmaceuticals (India) Private Limited offer?
Elis Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Health Conditions, Liver Care, Pain Relief, Heart Care.
Who are the key members and board of directors at Elis Pharmaceuticals (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Juneja  | Director | 01-Mar-2014 | Current |
| Sapna Kaushik | Director | 21-Apr-2022 | Current |
Financial Performance of Elis Pharmaceuticals (India).
Elis Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 18.88% decrease. The company also saw a substantial fall in profitability, with a 315.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elis Pharmaceuticals (India)?
In 2023, Elis Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 18 Oct 2021 | ₹1.61 M | Open |
Axis Bank Limited Creation Date: 19 Jul 2021 | ₹1.00 M | Open |
How Many Employees Work at Elis Pharmaceuticals (India)?
Unlock and access historical data on people associated with Elis Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elis Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elis Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
